BPCR:LSE:LSE-BioPharma Credit PLC (USD)

COMMON STOCK | Asset Management |

Last Closing

USD 0.854

Change

0.00 (0.00)%

Market Cap

USD 104.11B

Volume

0.17M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Asset Management

Symbol Name Price(Change) Market Cap
FP:LSE Fondul Proprietatea S.A. GDR

+0.04 (+0.88%)

USD 264.18B
MNTN:LSE Schiehallion Fund Ltd

N/A

USD 83.75B
RTW:LSE RTW Venture Fund Ltd

-0.01 (-0.33%)

USD 51.03B
TMI:LSE Taylor Maritime Investments Lt..

N/A

USD 33.09B
AMIF:LSE Amicorp FS (UK) PLC

N/A

USD 17.95B
USF:LSE US Solar Fund Plc

N/A

USD 14.31B
ICG:LSE Intermediate Capital Group PLC

+22.00 (+0.95%)

USD 5.96B
FCIT:LSE F&C Investment Trust PLC

+16.00 (+1.57%)

USD 5.04B
MNG:LSE M&G Plc

+3.10 (+1.50%)

USD 4.93B
BPT:LSE Bridgepoint Group Plc

+9.20 (+2.46%)

USD 2.90B

ETFs Containing BPCR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Asset Management) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.67% 47% F 45% F
Dividend Return 7.69% 100% F 98% N/A
Total Return 9.36% 75% C 68% D+
Trailing 12 Months  
Capital Gain -4.04% 33% F 27% F
Dividend Return 13.44% 98% N/A 99% N/A
Total Return 9.39% 30% F 51% F
Trailing 5 Years  
Capital Gain -19.05% 35% F 28% F
Dividend Return 38.95% 93% A 94% A
Total Return 19.90% 68% D+ 54% F
Average Annual (5 Year Horizon)  
Capital Gain -2.41% 31% F 31% F
Dividend Return 5.63% 30% F 60% D-
Total Return 8.04% 85% B 92% A
Risk Return Profile  
Volatility (Standard Deviation) 39.26% 20% F 23% F
Risk Adjusted Return 14.35% 31% F 51% F
Market Capitalization 104.11B 99% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.